x
Enter password to continue
x
Loading...
×
Stripes is an NYC-based growth equity firm led by entrepreneurs and operators. We invest in and actively support best-in-class, category-defining companies. We believe Isomorphic Labs will revolutionize drug discovery.
Stripes partners with founders building n-of-1, category-defining companies with enormous opportunity. We look for amazing products with amazing market opportunities.
| Company | Overview | Round |
|---|---|---|
| Leading data infrastructure platform | $10B, Dec 2024 | |
| Finance automation platform | $150M, Dec 2024 | |
| Autonomous mobility solutions | Undisclosed | |
| AI-powered public safety | $275M, Mar 2025 | |
| Premium athleisure brand | $825M, Nov 2024 |
Convergence of challenges require new approaches to R&D. Structural pressures across pharma are creating a generational opening for AI-native drug discovery.
| Metric | Then | Now | Trend |
|---|---|---|---|
| Avg. annual R&D expenditure (top 15) | $5.3B (2011-15) | $6.0B (2016-20) | ▲ Rising |
| Avg. years to complete Phase 2 & 3 | 6.5 years | 7.1 years | ▲ Worsening |
| Increasing Pressure | Challenging Backdrop | Resulting Impact |
|---|---|---|
| 50% decrease in years of MOA exclusivity (8 yrs in 2000-04 vs. 4 yrs in 2016+) | 53% of sites indicate insufficient bandwidth to run trials | 22% of trials have delays >40% |
| 40% increase in patient trial slots in oncology (2016-21) | 56% increase in trial complexity vs. 3 years ago | ~90% of drugs entering clinical trials ultimately fail |
Source: Schumacher "Analysis of pharma R&D productivity" (Oct 2023); Bain "Clinical Trials at a Crossroads" (Jan 2023); Bain "Benchmarking and TSR" (Oct 2023)
Top pharma companies are rationalizing trial portfolios — while smaller, more nimble companies (including AI-native biotechs) are driving the majority of new clinical activity.
| Year | Total Starts | "Others" Share | Growth |
|---|---|---|---|
| 2015 | 3,951 | 53% | +6% p.a. |
| 2020 | 5,213 | 69% | |
| 2021 | 6,368 (peak) | 72% | +7% p.a. |
| 2024 | 5,614 | 75% | -3% p.a. |
Source: Citeline Trialtrove as of July 2025; PharmaCo rankings by reported 2024 revenue
The industry has moved past experimentation — the question is no longer "if" but "how fast."
| Stage | Company | Use Case | Detail |
|---|---|---|---|
| Discovery | Moderna + IBM | mRNA Candidate ID | Using GenAI to rapidly identify new mRNA vaccine candidates |
| Discovery | AstraZeneca | ML Pattern Recognition | Partnering with academia to spot patterns between healthy, diseased, and drug-treated tissue |
| Development | Sanofi | Clinical Trial Optimization | Plai app identifies promising trial locations and participant information |
| Development | Eli Lilly + Yseop | Study Report Automation | Automating patient narratives and clinical study reports |
| Development | Pfizer + Concreto | Regulatory Filing | Accelerating outcome studies and regulatory submissions |
| Supply | Eli Lilly | Robotic Process AI | AI solutions to automate robotic manufacturing and identify inefficiencies |
| Launch | GSK + Tempus | Personalized Treatment | AI-enabled platform for personalized treatment; improving trial design |
| Launch | Novartis + Aktana | HCP Engagement | Better segmenting, engaging, and following up with healthcare providers |
Source: Bain GenAI in Pharma Survey (N=100), Sept 2023; Company websites and earnings calls
From new modalities to decentralized trials to ecosystem partnerships — the R&D landscape is transforming.
Source: Bain R&D Analysis; Industry participant interviews
Pharma is under unprecedented pressure to do more with less — creating a "burning platform" for AI-enabled drug discovery.
| Finding | Detail |
|---|---|
| Top 20 Pharma AI Adoption | 50% of Top 20 Pharma and 55% of $1B–$10B companies prioritize tool adoption |
| AI POC Penetration | >50% have POC for AI in R&D; only 15% in full rollout — massive whitespace |
| Vendor Scrutiny | 41% of sponsors being more cost-conscious with vendors |
| AI Governance | Pharma restricting AI to approved use cases — favors secure, enterprise-grade platforms like Isomorphic |
Stripes conducted expert calls with senior pharma and biotech leaders to validate Isomorphic's competitive position.
A category-defining company with an amazing product in a market worth winning.
AlphaFold 2 achieved 86% experimental accuracy in protein structure prediction — up from 40% prior state-of-art — declared "solved" by competition organizers.
Global pharma R&D spend is $351B and growing, but productivity declining. Phase 2/3 timelines extended to 7.1 years while MOA exclusivity windows halved.
Alphabet/DeepMind lineage provides unmatched talent — John Jumper (Nobel Prize, AlphaFold 2 inventor) and Demis Hassabis (Nobel Prize) are "outliers — rare talent not found in biopharma."
Expansion from protein structure prediction → small molecule design → ADMET optimization → clinical pharmacology.
| Dimension | Our Perspective | Market Commentary |
|---|---|---|
| DeepMind-Caliber AI | Foundation in AlphaFold, generalized to broader molecular modeling. Holistic diffusion-based approach. Trained on validated X-ray crystallography and NMR data. | "Models are way ahead because they approach the entire problem holistically" — Abbott Labs |
| Pipeline Breadth | Spans target ID, hit finding, lead optimization, ADMET, binding dynamics, co-folding. Aspires to predict full clinical pharmacology. | "Will aspire to predict affinities, clinical pharmacology, whole ADMET properties" — Eli Lilly |
| World-Class Team | Demis Hassabis (Nobel Prize) & John Jumper (Nobel Prize) lead a team combining frontier AI + deep biology. Attracts top talent from both AI and biopharma. | "These two are outliers — rare talent not typically found in biopharma" — Eli Lilly |
| Superior UX | Actionable insights for molecular screening, binding analysis, and target characterization with intuitive interface. | "More user-friendly… saving a lot of time… giving us new chemical space" — Estée Lauder |
Lilly's partnership with Isomorphic goes far beyond a technology platform deal — it is a deep scientific co-development with shared clinical upside.
| Dimension | Partner Insight |
|---|---|
| Partnership Model | Co-developing novel drug candidates together. "If we were to remove that they were a tech-first company, they are a true partner — we are co-developing assets with them." Intention to go to market jointly and share in the upside. |
| Strategic Rationale | Isomorphic finds novel molecular matter that traditional approaches cannot. Acts as both a complement and a backup — providing differentiated shots on goal beyond what Lilly's internal teams develop. |
| Scientific Depth | Not just technologists — Isomorphic performs in-vitro experimental validation alongside their models. Lilly pays for these services and for firewalling employees from competitors. |
| Data & IP | Isomorphic gains institutional knowledge from the partnership but does not train on Lilly's data. All partnership data stays with Lilly. No model advantage leakage to competitors. |
| Clinical Potential | "If anything we're collaborating on gets to Phase 1 it's an easy 5×. If anything gets to Phase 2 we would probably want to buy them." Clinical milestones are the name of the game. |
| Market Context | Lilly is the top spender on AI in pharma. Taking GLP-1 winnings and partnering broadly to find the next franchise. AI in drug discovery is still unproven — but Isomorphic is the bet they're making. |
AI drug discovery has attracted $3B+ in venture capital since 2022. The landscape spans point-solution startups, AI-native biotechs, and infrastructure plays. Below is a comprehensive map of the competitive terrain.
Closed-loop protein and antibody lead optimization — a pharma team brings a defined target and initial molecule, and Cradle proposes optimized variants that are experimentally tested.
Molecular interaction modeling and generative biologics — focused on early discovery where little or no starting molecule exists.
Sorted by funding raised. Pipeline stages color-coded to the drug development lifecycle.
| Company | Est. | Pipeline Stage | Specific Edge | Raised | Team |
|---|---|---|---|---|---|
| Xaira Therapeutics | 2024 | End-to-end | AI-native biotech integrating AI across discovery and early development for internal programs | ~$1B+ | 190 |
| Formation Bio | 2016 | Discovery Clinical | AI discovery paired with in-house drug development, advancing assets through clinical stages | ~$600M+ | 200 |
| Lila Sciences | 2023 | Discovery Lead Opt. | AI models + large-scale automated wet labs generating proprietary data for iterative refinement | $550M | 260 |
| Genesis Therapeutics | 2019 | Hit ID Lead Opt. | Physics-aware ML for small-molecule design on difficult targets using biophysical constraints | $250M | 150 |
| Profluent Bio | 2022 | Discovery Hit ID | Large generative protein models to design novel sequences beyond known scaffolds | ~$150M | 50 |
| Medra AI | 2025 | Hit ID | Autonomous small-molecule discovery loops combining AI with robotic wet-lab execution | $82M | 5 |
| Edison Scientific | 2025 | Discovery | Discovery support and hypothesis generation | $70M | 45 |
| Manas AI | 2023 | Discovery Preclinical | Rapidly designs and advances internal therapeutic programs — asset creation over software | $50M | 16 |
| Latent Labs | 2023 | Discovery | Frontier models for discovery support and hypothesis generation | $50M | 20 |
| Collate | 2025 | Infrastructure | Data management, experiment tracking, and workflow tooling for AI-native biotech | $30M | 23 |
| Axiom AI | 2024 | Infrastructure | Compute, analytics, and experimentation infrastructure for AI-driven biology | $30M | 23 |
| Boltz Bio | 2025 | Hit ID Lead Opt. | Biophysical modeling + ML for molecule design with structural and binding constraints | $28M | 6 |
| Ataraxis AI | 2023 | Discovery | Predictive models for molecular and biological outcomes across discovery workflows | $24M | 36 |
| Valinor Discovery | 2024 | Hit ID | AI small-molecule discovery grounded in biological context and target relevance | $13M | 12 |
| Numenos AI | 2023 | Hit ID | Early-stage molecular design models for initial hit generation and prioritization | $8M | 14 |
Current capabilities and expansion roadmap
AlphaFold structure prediction
Molecular screening & generation
Property optimization
Absorption, distribution, metabolism
Digital twins, trial design
Expand from small molecules into biologics (antibodies, ADCs, immunotherapies) — the largest and fastest-growing segments.
Deepen existing Eli Lilly & Novartis deals — expanded therapeutic areas, milestone/royalty triggers.
Internal drug candidates create asymmetric upside. Precedent EV for "very good quality" Phase 3 assets has doubled since 2021 to $3.4B.
All new DeepMind AI models flow to Isomorphic. Feedback loops from pharma partnerships accelerate model improvement.
Stripes' in-house Scale Team provides hands-on support across every critical function — not just capital, but execution firepower embedded alongside your team.
Executive search, org design, compensation benchmarking, employer branding
Brand positioning, content strategy, demand generation, event marketing
FP&A setup, audit readiness, legal counsel, entity structuring, tax strategy
Data infrastructure, KPI dashboards, customer analytics, pricing optimization
GTM strategy, enterprise sales playbooks, pipeline management, partnership sourcing
Procurement, vendor management, international expansion, systems & process design
Help design and staff the enterprise sales motion for pharma partnerships — including territory planning, pricing strategy, and customer success frameworks
Source and recruit senior commercial leaders with pharma/biotech experience — CRO, VP Sales, Head of Partnerships — through our proprietary network
Leverage advisory council relationships to open doors at top 20 pharma — warm intros to R&D decision-makers and Chief Digital Officers
Position Isomorphic as the category leader in AI drug discovery — conference strategy, media relations, case study development, and analyst engagement
Healthcare is a core vertical for Stripes. We've built category leaders across pharma services, health tech, clinical analytics, and digital health — giving us pattern recognition directly relevant to Isomorphic.
Pattern recognition: Across these investments we've learned how to sell complex technology platforms into pharma R&D organizations — long sales cycles, multi-stakeholder buying committees, compliance requirements, and the importance of clinical validation.
Deep conviction in AI infrastructure and applications — direct pattern recognition for Isomorphic's AI-native approach to drug discovery.
Senior leaders across pharma, health systems, payers, and life sciences — available to Isomorphic through our advisory councils and executive advisor network.
| Name | Company | Role | Resource |
|---|---|---|---|
| Greg Meyers | Bristol Myers Squibb | Chief Digital & Technology Officer | Tech Council |
| Jim Swanson | Johnson & Johnson | Global CIO | Tech Council |
| Ryan Snyder | Thermo Fisher Scientific | SVP & CIO | Tech Council |
| Jorge Populo | UnitedHealth Group | CIO | Tech Council |
| Michelle Greene | Cardinal Health | Global CIO | Tech Council |
| BJ Moore | Providence Healthcare | Former CIO | Tech Council |
| Daniel Barchi | CommonSpirit | CIO | Tech Council |
| Aimee Cardwell | UnitedHealth Group | Former EVP & CISO | CISO Council |
| James Beeson | Cigna | Former CISO | CISO Council |
| Nick Vigier | Oscar Health | CISO | CISO Council |
| Tiffany Inglis | Sera Prognostics | Chief Medical Officer | Exec. Advisor |
| David Weathington | Elevance | VP, Network & Value Based Solutions | Exec. Advisor |
| Mike Bowersox | Humana | Former Medicare President, Mid-Atlantic | Exec. Advisor |
| Michelle Carnahan | Thirty Madison | President | Exec. Advisor |
| Jason Parrot | Vida | SVP Enterprise Growth & Partnerships | Exec. Advisor |
Operating Partners work hands-on with portfolio companies. Council members provide strategic access to decision-makers across healthcare, technology, and enterprise leadership.
For Isomorphic: Our Tech Council and CISO Council include technology decision-makers at major pharma and healthcare companies (BMS, J&J, Thermo Fisher, UnitedHealth, Cardinal Health). These relationships provide warm introductions to prospective customers and give Isomorphic a direct line to the buyers who control AI procurement budgets.
Embedded C-suite operators — not just advisory, but hands-on execution support.
| Name | Background | Isomorphic Relevance |
|---|---|---|
| Paul Melchiorre | Former CRO, Anaplan | Enterprise sales motion — territory planning, pricing, repeatable large-deal playbooks |
| Scott Aronson | Former COO, Cloudera | Platform-as-a-service GTM — transitioning custom engagements to scalable offerings |
| Sharon Rothstein | Former Global CMO, Starbucks | Category leadership positioning — establishing Isomorphic as the definitive AI discovery platform |
| Julie Herendeen | Former CMO, Dropbox | Growth marketing — driving awareness and pipeline within pharma/biotech buyers |
Specialized councils of senior executives — direct access to decision-makers who can open doors and validate strategy.
×
We believe Isomorphic Labs can revolutionize drug discovery. Let's build the future of medicine together.